OptimizeRx Continues Webinar Series, Introducing Innovative Ideas for Transforming New Medication Launches
September 21 2020 - 7:31AM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies, physicians and
patients, will resume its webinar series this week with a panel of
industry experts and thought leaders presenting innovative ideas
for improving medication launches.
OptimizeRx is presenting this webinar in collaboration with the
Digital Health Coalition and Diligent Health Solutions. The
organizations have teamed up to address pain points in patient
adherence to new medications that present undesirable side-effects.
The discussion will focus on ways life science companies can
deliver more effective programs for such medications, and achieve
better outcomes for patients and their care teams.
A panel of industry experts will discuss a new case study of an
innovative and highly successful patient engagement
program that helped patients successfully navigate the side
effects of treatment and adhere to life-extending
therapy.
The panel will be moderated by Mark Bard, co-founder of The
DHC Group, and Rebecca Love, MSN, RN, principal of clinical
innovations for OptimizeRx. They will be joined by Mary Anne
Greenberg, CEO of Diligent Health Solutions; Eugene
Borukhovich, COO of YourCoach.Health and former Global Head Digital
Health at Bayer; and Chris DiCostanzo, vice president of
client relations at OptimizeRx.
Topic: Innovative Ideas to Transform
New Medication Launches: Case Study and Panel
DiscussionLaunching a new medication in a complex disease
state is often fraught with complications that can impact
medication adherence. While new medications can improve a patient’s
quality of life, they can also present significant side effects
that result in patients abandoning treatment. When patients are
faced with a life-threatening disease, unexpected or misunderstood
side effects can trigger fears that the medication is having an
adverse effect or worsening their condition.This webinar will
discuss innovative and best-in-practice approaches to new drug
launches that explore the art, science and psychology of treatment
and medication adherence. It will explore the complexities involved
but also the opportunities for life science companies to deliver
new programs that achieve positive outcomes for patients and their
care teams. Join this incredible panel of industry experts and
thought leaders who bring to the discussion decades of experience
in innovative drug launches.
Date: Thursday, September
24Time: 1:00 p.m. ET
The webinar is free and open to anyone in the
industry interested
in participating in a practical conversation
with industry leaders.
Register today
at www.optimizerx.com/webinars.
About OptimizeRxOptimizeRx is a digital health
company that provides communications solutions for life science
companies, physicians and patients. Connecting over half of
healthcare providers in the U.S. and millions of patients through a
proprietary network, the OptimizeRx digital health platform helps
patients afford and stay on medications. The platform unlocks new
patient and physician touchpoints for life science companies along
the patient journey, from point-of-care, to retail pharmacy,
through mobile patient engagement.
For more information, follow the company
on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
OptimizeRx Contact Doug Baker, CFOTel
(248) 651-6568 (x807)dbaker@optimizerx.com
Media Relations Contact Maira Alejandra,
Media Relations ManagerTel (754)
245-7070 malejandra@optimizerx.com
Investor Relations Contact Ron Both or
Grant Stude, CMA Tel (949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024